Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Retained Earnings (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Retained Earnings for 15 consecutive years, with -$923.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings changed 0.43% year-over-year to -$923.7 million, compared with a TTM value of -$923.7 million through Sep 2025, changed 0.43%, and an annual FY2024 reading of -$920.4 million, down 0.51% over the prior year.
  • Retained Earnings was -$923.7 million for Q3 2025 at Alaunos Therapeutics, roughly flat from -$922.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$785.7 million in Q1 2021 and bottomed at -$923.7 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$883.9 million, with a median of -$899.4 million recorded in 2023.
  • The sharpest move saw Retained Earnings dropped 12.11% in 2021, then decreased 0.28% in 2025.
  • Year by year, Retained Earnings stood at -$842.9 million in 2021, then fell by 4.48% to -$880.6 million in 2022, then dropped by 3.99% to -$915.8 million in 2023, then dropped by 0.51% to -$920.4 million in 2024, then decreased by 0.35% to -$923.7 million in 2025.
  • Business Quant data shows Retained Earnings for TCRT at -$923.7 million in Q3 2025, -$922.6 million in Q2 2025, and -$921.5 million in Q1 2025.